{"product_id":"cst-74398s","title":"CST,  74398S, Human RANKL Recombinant Protein","description":"Growth Factors and Cytokines for studying TNFSF11 in the research area.\n\n\u003cb\u003eStorage\u003c\/b\u003e\nHuman RANKL Recombinant Protein is supplied as lyophilized material that is very stable at -20ºC. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg\/mL which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Once in solution, store at 4ºC and use within 1 month, or store at -20ºC to -80ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze\/thaw cycles if storing reconstituted material at -20ºC to -80ºC.\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nRecombinant hRANKL was expressed in and is supplied in a lyophilized form.\n\u003cb\u003eBackground\u003c\/b\u003e\nRANKL, also known as TRANCE or OPGL, is a member of the TNF superfamily of ligands. T cells, mammary epithelial cells, and endothelial cells can produce RANKL (1). RANKL is expressed as a type II transmembrane protein or cleaved into a soluble form by extracellular proteases, such as TACE, ADAM10, and matrix metalloproteases (1). Alternative splicing also results in the production of soluble RANKL (1). RANKL signaling is antagonized by osteoprotegerin, which functions as a soluble decoy receptor (2). RANKL plays key roles in mammary gland development and dendritic cell survival and is required for osteoclast differentiation and survival (3-6). Research studies have shown that RANKL deficiencies in both mice and humans are associated with abnormally increased bone density and defects in lymphoid organogenesis (5,6).","brand":"CST","offers":[{"title":"Default Title","offer_id":46800716398761,"sku":"74398S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-74398s","provider":"Iright","version":"1.0","type":"link"}